BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28941024)

  • 1. Association of High Mobility Group Box Chromosomal Protein 1 and Receptor for Advanced Glycation End Products Serum Concentrations With Extraglandular Involvement and Disease Activity in Sjögren's Syndrome.
    Kanne AM; Jülich M; Mahmutovic A; Tröster I; Sehnert B; Urbonaviciute V; Voll RE; Kollert F
    Arthritis Care Res (Hoboken); 2018 Jun; 70(6):944-948. PubMed ID: 28941024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity.
    Yoshizaki A; Komura K; Iwata Y; Ogawa F; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Clin Immunol; 2009 Mar; 29(2):180-9. PubMed ID: 18825489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Yamada S; Takeuchi M; Fukami K; Ueda S; Adachi H; Matsui T; Okuda S; Yamagishi S
    Metabolism; 2009 Nov; 58(11):1624-8. PubMed ID: 19604520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjögren's syndrome.
    Stewart C; Cha S; Caudle RM; Berg K; Katz J
    Rheumatol Int; 2008 Jun; 28(8):771-6. PubMed ID: 18231794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjögren's syndrome.
    Dupire G; Nicaise C; Gangji V; Soyfoo MS
    Scand J Rheumatol; 2012 Mar; 41(2):120-3. PubMed ID: 22248244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological lymphocytic activity and patient-reported outcomes in Sjögren's syndrome.
    Jülich M; Kanne AM; Sehnert B; Budweiser S; Voll RE; Kollert F
    Clin Rheumatol; 2018 Sep; 37(9):2361-2366. PubMed ID: 29858711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study.
    Zakiyanov O; Kriha V; Vachek J; Zima T; Tesar V; Kalousova M
    BMC Nephrol; 2013 Nov; 14():245. PubMed ID: 24188108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
    Seror R; Gottenberg JE; Devauchelle-Pensec V; Dubost JJ; Le Guern V; Hayem G; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Morel J; Pedriger A; Puechal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Zarnitsky C; Labetoulle M; Ravaud P; Mariette X
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjögren's syndrome.
    Ek M; Popovic K; Harris HE; Nauclér CS; Wahren-Herlenius M
    Arthritis Rheum; 2006 Jul; 54(7):2289-94. PubMed ID: 16802368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between increased circulating YKL-40, IL-6 and TNF-α levels and phenotypes and disease activity of primary Sjögren's syndrome.
    Chen C; Liang Y; Zhang Z; Zhang Z; Yang Z
    Int Immunopharmacol; 2020 Nov; 88():106878. PubMed ID: 32791244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands.
    Quartuccio L; Salvin S; Fabris M; Maset M; Pontarini E; Isola M; De Vita S
    Rheumatology (Oxford); 2013 Feb; 52(2):276-81. PubMed ID: 22879463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum 25-Hydroxyvitamin D3 and BAFF Levels Are Associated with Disease Activity in Primary Sjogren's Syndrome.
    Lee SJ; Oh HJ; Choi BY; Jang YJ; Lee JY; Park JK; Song YW
    J Immunol Res; 2016; 2016():5781070. PubMed ID: 28074193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-centromere antibody-positive Sjögren's syndrome: A distinct clinical subgroup?
    Lee KE; Kang JH; Lee JW; Wen L; Park DJ; Kim TJ; Park YW; Lee SS
    Int J Rheum Dis; 2015 Sep; 18(7):776-82. PubMed ID: 26179502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors.
    Quartuccio L; Gandolfo S; Zabotti A; Zandonella Callegher S; Fabro C; De Vita S
    Front Immunol; 2019; 10():1527. PubMed ID: 31354708
    [No Abstract]   [Full Text] [Related]  

  • 15. Impaired degradation and aberrant phagocytosis of necrotic cell debris in the peripheral blood of patients with primary Sjögren's syndrome.
    Fragoulis GE; Vakrakou AG; Papadopoulou A; Germenis A; Kanavakis E; Moutsopoulos HM; Manoussakis MN
    J Autoimmun; 2015 Jan; 56():12-22. PubMed ID: 25228497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of definitive serum biomarkers associated with disease activity in primary Sjögren's syndrome.
    Nishikawa A; Suzuki K; Kassai Y; Gotou Y; Takiguchi M; Miyazaki T; Yoshimoto K; Yasuoka H; Yamaoka K; Morita R; Yoshimura A; Takeuchi T
    Arthritis Res Ther; 2016 May; 18(1):106. PubMed ID: 27180164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between serum-soluble receptor for advanced glycation end products (sRAGE) and disease activity in rheumatoid arthritis patients.
    Jafari Nakhjavani MR; Jafarpour M; Ghorbanihaghjo A; Abedi Azar S; Malek Mahdavi A
    Mod Rheumatol; 2019 Nov; 29(6):943-948. PubMed ID: 30474471
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperviscosity in primary Sjögren's syndrome: clinical implications.
    Hernández-Molina G; Bermúdez-Bermejo P
    Int J Rheum Dis; 2017 Jan; 20(1):84-89. PubMed ID: 26807556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced expression of NLRP3 inflammasome-related inflammation in peripheral blood mononuclear cells in Sjögren's syndrome.
    Kim SK; Choe JY; Lee GH
    Clin Chim Acta; 2017 Nov; 474():147-154. PubMed ID: 28965771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index.
    Seror R; Mariette X; Bowman S; Baron G; Gottenberg JE; Bootsma H; Theander E; Tzioufas A; Vitali C; Ravaud P;
    Arthritis Care Res (Hoboken); 2010 Apr; 62(4):551-8. PubMed ID: 20391511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.